AVITA Medical Inc
NASDAQ:RCEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AVITA Medical Inc
NASDAQ:RCEL
|
US |
|
Genesis Energy LP
NYSE:GEL
|
US |
|
A
|
Amper SA
SWB:APR
|
ES |
|
A
|
Aspeed Technology Inc
TPEX:5274
|
TW |
|
Amper SA
LSE:0NO6
|
ES |
|
Forbo Holding AG
SIX:FORN
|
CH |
|
S
|
Solteq Oyj
OMXH:SOLTEQ
|
FI |
|
L
|
Lim Seong Hai Capital Bhd
KLSE:LSH
|
MY |
|
Netcall PLC
LSE:NET
|
UK |
|
P
|
Prosperity Bancshares Inc
XBER:PPY
|
US |
|
B
|
Bukit Sembawang Estates Ltd
XMUN:B1W1
|
SG |
|
Tidewater Inc
NYSE:TDW
|
US |
AVITA Medical Inc
AVITA Medical makes regenerative skin repair products used by doctors to treat severe wounds, burns, and other skin injuries. Its main product is a medical device system that prepares a patient’s own skin cells and spray them onto damaged tissue, helping the body close and heal the area without relying on a traditional skin graft. The company sells to hospitals, burn centers, and specialty clinics that treat complex wounds. The company earns money by selling its treatment systems, disposable cartridges, and related consumables used each time a procedure is performed. It also supports customers with training and clinical education so medical teams can use the procedure properly. Because the products are tied to repeat procedures, part of the business comes from ongoing use rather than a one-time device sale. AVITA’s role in healthcare is different from a standard wound-care supplier because it offers a cell-based treatment that uses the patient’s own skin as the raw material. That puts it between traditional surgery, biologic healing products, and advanced wound care. Its business depends on adoption by hospitals and specialists that handle difficult wounds where faster skin repair can improve care outcomes.
AVITA Medical makes regenerative skin repair products used by doctors to treat severe wounds, burns, and other skin injuries. Its main product is a medical device system that prepares a patient’s own skin cells and spray them onto damaged tissue, helping the body close and heal the area without relying on a traditional skin graft. The company sells to hospitals, burn centers, and specialty clinics that treat complex wounds.
The company earns money by selling its treatment systems, disposable cartridges, and related consumables used each time a procedure is performed. It also supports customers with training and clinical education so medical teams can use the procedure properly. Because the products are tied to repeat procedures, part of the business comes from ongoing use rather than a one-time device sale.
AVITA’s role in healthcare is different from a standard wound-care supplier because it offers a cell-based treatment that uses the patient’s own skin as the raw material. That puts it between traditional surgery, biologic healing products, and advanced wound care. Its business depends on adoption by hospitals and specialists that handle difficult wounds where faster skin repair can improve care outcomes.
Revenue: AVITA reported first-quarter revenue of approximately $19.3 million, up 4% year over year and about 10% sequentially, which management said was the company’s highest quarterly revenue in the past year.
Demand: Management said the business is shifting toward more frequent, smaller orders and more predictable procedure-driven demand, helped by improving RECELL utilization and early Cohealyx adoption.
Guidance: The company reaffirmed full-year 2026 net revenue guidance of $80 million to $85 million and full-year operating expense guidance of $80 million to $85 million.
RECELL: All 7 Medicare Administrative Contractors have now published payment rates for clinician use, and management said reimbursement uncertainty is easing as utilization patterns normalize.
Cash: Cash used in the quarter was approximately $9.9 million, and management expects a significant decline in cash use in Q2 as timing effects reverse and collections improve.
Cohealyx: Early adoption is building, supported by interim clinical data showing about 20 days to graft readiness versus benchmark and a median time to grafting of about 11 days.
BARDA: AVITA said the BARDA agreement includes about $3.9 million of guaranteed revenue over 10 years, or roughly $100,000 per quarter, with additional upside only in a mass-casualty event.
